Pharmacogenomics Blood Sampling Protocol For Irinotecan/Fluorouracil/Leucovorin(CPT-11/FU/LV).

Back to Search
Print
Bookmark Trial

NCT00140036

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Mobile, Alabama, 36608, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Colorectal Neoplasms
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Participation in studies employing treatment with irinotecan and a signed informed consent.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- None.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now
pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
Learn more ›

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Colorectal NeoplasmsPharmacogenomics Blood Sampling Protocol For Irinotecan/Fluorouracil/Leucovorin(CPT-11/FU/LV).
NCT00140036
  1. Mobile, Alabama
  2. Tucson, Arizona
  3. Fresno, California
  4. Stamford, Connecticut
  5. Washington, District of Columbia
  6. Jacksonville, Florida
  7. New Port Richey, Florida
  8. Tamarac, Florida
  9. Rockford, Illinois
  10. Terre Haute, Indiana
  11. New Orleans, Louisiana
  12. Annapolis, Maryland
  13. Pittsfield, Massachusetts
  14. Minneapolis, Minnesota
  15. Columbia, Missouri
  16. Billings, Montana
  17. Las Vegas, Nevada
  18. Hooksett, New Hampshire
  19. Lebanon, New Hampshire
  20. Rockville Centre, New York
  21. Greenville, North Carolina
  22. Hendersonville, North Carolina
  23. Hickory, North Carolina
  24. Winston - Salem, North Carolina
  25. Zanesville, Ohio
  26. Charleston, South Carolina
  27. Temple, Texas
  28. Newport News, Virginia
  29. Milwaukee, Wisconsin
  30. Halifax, Nova Scotia
  31. Kingston, Ontario
  32. Kitchener, Ontario
  33. Windsor, Ontario
  34. Fleurimont, Quebec
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Colorectal NeoplasmsAssessment Of Safety And Efficacy Of SU11248 In Patients With Metastatic Colorectal Cancer Who Have Failed Selected Previous Treatments.
NCT00077987
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Colorectal NeoplasmsStudy Of Sunitinib In Combination With Folfox In Patients With Colorectal Cancer
NCT00631410
  1. Kashiwa, Chiba
  2. Suntougun, Shizuoka
  3. Chuo-ku, Tokyo
ALL GENDERS
20 Years+
years
MULTIPLE SITES
Colorectal NeoplasmsStudy of the GARFT Inhibitor AG2037 in Patients With Metastatic Colorectal Cancer Who Failed Treatment
NCT00078468
  1. Poway, California
  2. Washington, District of Columbia
  3. Tampa, Florida
  4. New York, New York
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Pharmacogenomics Blood Sampling Protocol For Irinotecan/Fluorouracil/Leucovorin(CPT-11/FU/LV).
Official Title  ICMJE Pharmacogenomics Blood Sampling Protocol For Irinotecan/Fluorouracil/Leucovorin(CPT-11/FU/LV).
Brief Summary This protocol describes procedures for the collection of blood samples for the intent of determining genetic contribution to the safety and efficacy of CPT/FU/LV.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Colorectal Neoplasms
Intervention  ICMJE Procedure: Blood draw
Study Arms  ICMJE Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Enrollment  ICMJE
 (submitted: August 30, 2005)		137
Original Enrollment  ICMJE Same as current
Study Completion Date  ICMJE August 2005
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Participation in studies employing treatment with irinotecan and a signed informed consent.

Exclusion Criteria:

  • None.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Canada,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00140036
Other Study ID Numbers  ICMJE CPTAIV-0020-366
A5961020
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Not Provided
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date February 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP